2 completed, 1 unknown. 2 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow SAB-185: new trials by email Literature Review of SAB-185 trials Research Report on SAB-185
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19 SAB-185, Normal Saline - COVID-19, SARS-CoV2 | Phase 1 | Unknown | SAb Biotherapeutics, Inc. | 21 | 2020-08-20 | 2021-10-26 |
| ACTIV-2: A Study for Outpatients With COVID-19 bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19 | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 4044 | 2020-08-19 | 2024-08-02 |
| Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants SAB-185, Normal saline - COVID-19, SARS-CoV2 | Phase 1 | Completed | SAb Biotherapeutics, Inc. | 28 | 2020-07-01 | 2022-07-01 |
COVID-19 (3) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Nidovirales Infections (1) · RNA Virus Infections (1) · Severe Acute Respiratory Syndrome (1) · Virus Diseases (1)
SAb Biotherapeutics, Inc. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (3) · Argentina (1) · Brazil (1) · Canada (1) · Guatemala (1) · Mexico (1) · Philippines (1) · Puerto Rico (1) · South Africa (1)
David Hoover, MD (2) · David Smith, MD, MAS (1)
PMID 34473343, PMID 34981077, PMID 35713300, PMID 35793677, PMID 35797235, PMID 35995785, PMID 36210483, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36467293, PMID 36661240, PMID 36802755, PMID 37068272, PMID 37099295, PMID 37279602, PMID 37650230, PMID 37650232, PMID 37650233, PMID 37650236, PMID 37855026, PMID 39018444, PMID 39028902, PMID 42148571